Disease-Specific Factors Associated with Readmissions or Mortality After Hospital Discharge in COVID-19 Patients: a Retrospective Cohort Study

• Published in: Journal of general internal medicine : JGIM 2022-11, Vol.37 (15), p.3973-3978
• Main Authors: Huang, Cheng-Wei, Park, Joon S., Song, Hubert, Khang, Vang Kou, Yu, Albert S., Nguyen, Huong Q., Lee, Janet S., Subject, Christopher C., Shen, Ernest
• Format: Article
• Language: English
• Subjects: Adult; Adverse events; Aftercare; Antiviral drugs; Cohort analysis; Confidence intervals; Coronaviruses; COVID-19; COVID-19 - therapy; Decision making; Health care facilities; Health services; Hospitals; Humans; Internal Medicine; Medical treatment; Medicine; Medicine & Public Health; Mortality; Original Research; Patient Discharge; Patient Readmission; Patients; Retrospective Studies; SARS-CoV-2; Statistical analysis; Viral diseases
• ISSN: 0884-8734; 1525-1497
• DOI: 10.1007/s11606-022-07610-5

Background Understanding the implications of disease-specific factors beyond baseline patient characteristics for coronavirus disease 2019 (COVID-19) may allow for identification of indicators for safe hospital discharge. Objective Assess whether disease-specific factors are associated with adverse events post-discharge using a data-driven approach. Design Retrospective cohort study. Setting Fifteen medical centers within Kaiser Permanente Southern California. Participants Adult patients ( n =3508) discharged alive following hospitalization for COVID-19 between 05/01/2020 and 09/30/2020. Interventions None. Main Measures Adverse events defined as all-cause readmission or mortality within 14 days of discharge. Least absolute shrinkage and selection operator (LASSO) was used for variable selection and logistic regression was performed to estimate odds ratio (OR) and 95% confidence interval (CI). Key Results Four variables including age, Elixhauser index, treatment with remdesivir, and symptom duration at discharge were selected by LASSO. Treatment with remdesivir was inversely associated with adverse events (OR: 0.46 [95%CI: 0.36–0.61]), while symptom duration ≤ 10 days was associated with adverse events (OR: 2.27 [95%CI: 1.79–2.87]) in addition to age (OR: 1.02 [95%CI: 1.01–1.03]) and Elixhauser index (OR: 1.15 [95%CI: 1.11–1.20]). A significant interaction between remdesivir and symptom duration was further observed ( p =0.01). The association of remdesivir was stronger among those with symptom duration ≤10 days vs >10 days at discharge (OR: 0.30 [95%CI: 0.19–0.47] vs 0.62 [95%CI: 0.44–0.87]), while the association of symptom duration ≤ 10 days at discharge was weaker among those treated with remdesivir vs those not treated (OR: 1.31 [95%CI: 0.79–2.17] vs 2.71 [95%CI 2.05–3.59]). Conclusions Disease-specific factors including treatment with remdesivir, symptom duration, and their interplay may help guide clinical decision making at time of discharge.